Maravai Q2 adjusted EPS misses estimates
Overview
Maravai Q2 revenue falls 31.7% yr/yr, meeting analyst expectations, per LSEG data
Adjusted EPS and EBITDA miss analyst estimates, per LSEG data
Co earlier announced restructuring for $50 mln annualized cost savings
Outlook
Maravai withdraws 2025 revenue guidance amid leadership transition
Company expects positive adjusted EBITDA by second half 2026
Maravai targets $50 mln in annualized cost savings
Restructuring charges estimated at $8-9 mln in H2 2025
Result Drivers
REVENUE DECLINE - Nucleic Acid Production revenue fell 43.1% due to lack of high-volume CleanCap orders for vaccine programs
RESTRUCTURING - Co targets over $50 mln in annualized cost savings through labor, facilities, capex and productivity initiatives
BIOLOGICS SAFETY TESTING - Revenue grew 9.9% driven by demand for Host Cell Protein kits and MockV viral clearance kits
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Meet | $47.40 mln | $47.40 mln (12 Analysts) |
Q2 Adjusted EPS | Miss | -$0.08 | -$0.07 (11 Analysts) |
Q2 EPS |
| -$0.27 |
|
Q2 Adjusted EBITDA | Miss | -$10.40 mln | -$8.39 mln (9 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Maravai LifeSciences Holdings Inc is $5.00, about 56% above its August 8 closing price of $2.20
Press Release: ID:nGNX38xcQh
